Clinical Trial Update: Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

View source ↗

Summary

A completed clinical trial evaluating cell damage from alkylating agents in patients with acute myeloid leukemia, myelodysplastic syndromes, and Fanconi anemia,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Fanconi Anemia
• Myelodysplastic Syndromes

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Leukemia, Myelodysplastic Syndromes | Status: COMPLETED